Literature DB >> 19671040

HIF prolyl-4-hydroxylase interacting proteins: consequences for drug targeting.

Roland H Wenger1, Gieri Camenisch, Daniel P Stiehl, Dörthe M Katschinski.   

Abstract

Protein stability of hypoxia-inducible factor (HIF)alpha subunits is regulated by the oxygen-sensing prolyl-4-hydroxylase domain (PHD) enzymes. Under oxygen-limited conditions, HIFalpha subunits are stabilized and form active HIF transcription factors that induce a large number of genes involved in adaptation to hypoxic conditions with physiological implications for erythropoiesis, angiogenesis, cardiovascular function and cellular metabolism. Oxygen-sensing is regulated by the co-substrate-dependent activity and hypoxia-inducible abundance of the PHD enzymes which trigger HIFalpha stability even under low oxygen conditions. Because HIFalpha itself is notoriously reluctant to the development of antagonists, an increase in PHD activity would offer an interesting alternative to the development of drugs that interfere specifically with the HIF signalling pathway. Interestingly, among the recently discovered PHD interacting proteins were not only novel downstream targets but also upstream regulators of PHDs. Their PHD isoform-specific interaction offers the possibility to target distinct PHD isoforms and their non-identical downstream signalling pathways. This review summarizes our current knowledge on PHD interacting proteins, including upstream regulators, chaperonins, scaffolding proteins, and novel downstream transcription factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19671040     DOI: 10.2174/138161209789649411

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  3 in total

1.  Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.

Authors:  Sreenivasulu Chintala; Tanbir Najrana; Karoly Toth; Shousong Cao; Farukh A Durrani; Roberto Pili; Youcef M Rustum
Journal:  BMC Cancer       Date:  2012-07-17       Impact factor: 4.430

2.  Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun N-terminal kinase 1 prevents cellular hypoxic damage.

Authors:  Seema Betigeri; Min Zhang; Olga Garbuzenko; Tamara Minko
Journal:  Drug Deliv Transl Res       Date:  2010-12-14       Impact factor: 4.617

Review 3.  Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges.

Authors:  Jonathan Michael Harnoss; Moritz Johannes Strowitzki; Praveen Radhakrishnan; Lisa Katharina Platzer; Julian Camill Harnoss; Thomas Hank; Jun Cai; Alexis Ulrich; Martin Schneider
Journal:  Hypoxia (Auckl)       Date:  2015-01-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.